产品
编 号：F486296
分子式：C20H25NO2
分子量：311.42
分子式：C20H25NO2
分子量：311.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
结构图
CAS No: 864668-87-1
产品详情
生物活性：
ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
体内研究：
ENMD-1198 (200 mg/kg; p.o.; daily from day 7 to day 19) effectively inhibits growth of hepatocellular carcinoma through direct effects on the tumor cells, and also through inhibition of angiogenesis.Animal Model:Eight-week-old male athymic nude mice (BALB/c nu/nu) (xenografted hepatocellular tumors)
Dosage:200 mg/kg
Administration:P.o.; daily from day 7 to day 19
Result:Led to a significant growth inhibition of xenografted hepatocellular tumors.
体外研究：
ENMD-1198 (0-5 μM; 24 hours) leads to a significant dose-dependent inhibition of HCC cell growth with IC50s of 2.5 μM for HUH-7 and HepG2 cells, respectively.ENMD-1198 (2.5 μM; 16 hours) abrogates EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2).
ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
体内研究：
ENMD-1198 (200 mg/kg; p.o.; daily from day 7 to day 19) effectively inhibits growth of hepatocellular carcinoma through direct effects on the tumor cells, and also through inhibition of angiogenesis.Animal Model:Eight-week-old male athymic nude mice (BALB/c nu/nu) (xenografted hepatocellular tumors)
Dosage:200 mg/kg
Administration:P.o.; daily from day 7 to day 19
Result:Led to a significant growth inhibition of xenografted hepatocellular tumors.
体外研究：
ENMD-1198 (0-5 μM; 24 hours) leads to a significant dose-dependent inhibition of HCC cell growth with IC50s of 2.5 μM for HUH-7 and HepG2 cells, respectively.ENMD-1198 (2.5 μM; 16 hours) abrogates EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备